Investigational Drug Information for Gepotidacin
✉ Email this page to a colleague
What is the drug development status for Gepotidacin?
Gepotidacin is an investigational drug.
There have been 12 clinical trials for Gepotidacin.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 17th 2019.
The most common disease conditions in clinical trials are Bacterial Infections, Communicable Diseases, and Infections. The leading clinical trial sponsors are GlaxoSmithKline, Biomedical Advanced Research and Development Authority, and Barda (Contract No HHSO100201300011C).
There are three US patents protecting this investigational drug and one hundred and nine international patents.
Summary for Gepotidacin
| US Patents | 3 |
| International Patents | 109 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 22 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2019-10-17) |
| Vendors | 34 |
Recent Clinical Trials for Gepotidacin
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) | GlaxoSmithKline | Phase 3 |
| A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants | GlaxoSmithKline | Phase 1 |
| Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue | Medizinischen Universität Wien | Phase 1 |
Clinical Trial Summary for Gepotidacin
Top disease conditions for Gepotidacin
Top clinical trial sponsors for Gepotidacin
US Patents for Gepotidacin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gepotidacin | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Gepotidacin | ⤷ Sign Up | Mutagenizing intracellular nucleic acids | BIOLOGICAL RESEARCH CENTRE (Szeged, HU) | ⤷ Sign Up |
| Gepotidacin | ⤷ Sign Up | Anti-wall teichoic antibodies and conjugates | Genentench, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gepotidacin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gepotidacin | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Gepotidacin | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Gepotidacin | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Gepotidacin | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
